GS
CNTX icon

GTS Securities’s Context Therapeutics CNTX Stock Holding History

GTS Securities’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,176
Closed -$28.9K – 1452
2025
Q2 		$28.9K Buy
+44,176
New +$31.8K ﹤0.01% 1179

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GTS Securities's CNTX Position: Q3 2025 in Review

GTS Securities sold out of Context Therapeutics (CNTX) in Q3 2025, closing a stake of 44,176 shares — an estimated $28.9K sold.

GTS Securities first reported a position in CNTX in Q2 2025 and held it in 1 quarter. The position peaked at $28.9K in Q2 2025. 37 funds tracked by Wall St. Rank hold CNTX as of Q3 2025.

  • GTS Securities reported no remaining Context Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GTS Securities sold 44,176 Context Therapeutics shares in Q3 2025, an estimated $28.9K.
  • GTS Securities first reported a position in Context Therapeutics in Q2 2025 and held it in 1 quarter.
  • GTS Securities's Context Therapeutics position peaked at $28.9K in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2025.

Based on GTS Securities's 13F filing for Q3 2025, filed 14 Nov 2025.